Metod Oblak
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, interferon and immune responses, Palliative Care and End-of-Life Issues, Cancer survivorship and care
Most-Cited Works
- → Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care(2022)54 cited
- → Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study(2019)26 cited
- → Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study(2020)18 cited
- → Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3(2019)18 cited
- → Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma(2018)15 cited
- → Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO(2020)6 cited
- → Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3(2015)3 cited